- Trial phase
- Approved
- Time to market
- Already on the market since 2015 (US) and 2018 (EU). The latest expanded indication was approved in September 2025 (US) and July 2026 (EU pediatric).
- Why 4/10
- No hard binary catalyst (PDUFA / pivotal readout) is scheduled for VONVENDI in the next 12 months; it is an already-approved, marketed product. The drug is a minor contributor to Takeda (a large diversified pharma with ~JPY 4.5 trillion revenue), so even the expanded September 2025 approval was not a company-level binary event.
With VONVENDI's expanded FDA approval already secured (September 2025) and no pending PDUFA or pivotal readout on the horizon, the stock-moving catalyst for Takeda related to this drug has passed. Watch Takeda's quarterly earnings (next: H1 FY2026, reported October 29, 2026) for VONVENDI sales growth as a signal of commercial execution under the expanded label, but this single product is too small to drive Takeda's share price directionally.
Price Chart
Executive Summary
VONVENDI (vonicog alfa / recombinant von Willebrand factor) is Takeda's approved treatment for von Willebrand disease, the most common inherited bleeding disorder. First approved in 2015 for on-demand adult use, its label was significantly expanded in September 2025 to cover routine prophylaxis for adults with all VWD types and on-demand/perioperative use in children. VONVENDI is the only recombinant (non-plasma-derived) VWF therapy on the market, differentiating it from older plasma-derived products like Humate-P. Sales reached JPY 16.2 billion (~$108M) in FY2025, growing 32.5% year-over-year, driven by the expanded indication. However, VONVENDI represents a tiny fraction of Takeda's overall revenue (~0.4%), and no upcoming binary catalysts exist for this drug.
How It Works
VONVENDI is a lab-made (recombinant) copy of von Willebrand factor, a protein the body needs for normal blood clotting. People with von Willebrand disease (VWD) are born deficient or lacking this protein, so they bruise and bleed easily. VONVENDI replaces the missing protein, restoring the blood's ability to clot and stopping or preventing bleeding episodes.
Trial Status
VONVENDI was initially FDA-approved in 2015 for on-demand treatment of bleeding episodes in adults based on Phase 3 data. A supplemental BLA expanded approval in 2022 for prophylaxis in adults with severe Type 3 VWD. In September 2025, FDA approved a major label expansion to include routine prophylaxis for adults with all VWD types (1, 2 and 3) plus on-demand and perioperative use in pediatric patients, supported by additional Phase 3 and Phase 3b studies. The EU counterpart, Veyvondi, received pediatric approval from EMA in 2026.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for VONVENDI specifically; it is an approved, marketed drug with no pending PDUFA dates or pivotal readouts. Takeda's next relevant catalyst would be quarterly earnings reports where VONVENDI sales growth trajectory is disclosed.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report